Q: Further to your response to Tom on Dec. 5th, could you recommend several ETFs that would be quality choices to represent emerging markets, healthcare and tech that would result in less overall volatility than purchasing individual stocks? Thanks.
Q: Hi
I am down quite a bit on SNN? I am temped to sell for a tax loss and replace with xlv or IHI but am concerned that xlv or ihi as etfs do not have the same bounce potential as snn. is there another healthcare stock you can recommend or would you replace with xlv or ihi?
thanks
Q: Can you give your opinion on Zymeworks, please. It's been awhile and this company has made some links with big players. Thanks for your excellent service.
From prior responses, it aligned with right now having a high valuation even after the past years negative performance. Is this a good entry point? This has been on my watchlist for years now and each time I look at it, the valuation is too expensive. But with the recent drop is this a good entry point or do you think the market is signalling that growth is slowing down?
Q: I bought some medical start-ups in private placements around 2004 through 2007, including TMD Titan Medical. I bought into the both the Canadian and the US private placements. TMD has had a number of frustrating round-trips. Yesterday December 5, TMD stock saw considerable action both sides of border: opened yesterday at 0.90 Canadian , went up 40% to 1.25 closing the day at C$1.15 on high volume. Collapsed this morning. I see no news to explain the swing. The company sent shareholders anote about a strategic review. Perhaps a takeover is in the wings? Do you have any news on TMD? Would you hold or sell? (Tax loss not useable).
Q: With the Horizon announcement that there are 2 (named) possible acquirers (by Jan.23/23), would you wait or, after the recent jump, take the money and run?
Q: Your thoughts and comments please. Seems they are going in the right direction but market showing the opposite. What am I missing? Is it the hurricanes?
Q: Thanks for your useful answer. My info is that while legalization of pot in the US is not on the cards for the moment, a bill called the Safe Banking Act (in the US) is expected to pass in 2023 whose passage will allow institutional participation in the sector, which is something they cannot presently do, and a surge in purchases with significant associated price rises is anticipated as a result. This is some way out in front but the markets anticipate and I wondered how much of a hill Canopy for example had to climb, here or in the US.
Q: Hi there. Can you please comment on Biotech as a sector. Particularly the U.S. Would you say that it has been crashed equally or greater that Software. How do you like it’s potential over the next 12-24 months
Q: Abbott is kind of a sleeper, and I would like to sell for a tax loss. Would you agree with this or is it more of a buy at this price? What equity would be similar to ABT as a replacement?
Thank You!
Albert
Q: I'm a Loyal Holder of Savaria. Like the Company. Past month stock has risen 17%. Has there been any news of late? And what do you forecast for the Future. Thanks so much. Barry from Montréal